STOCK TITAN
  1. Home
  2. News
  3. SLGC

SomaLogic, Inc. - SLGC STOCK NEWS

Welcome to our dedicated page for SomaLogic news (Ticker: SLGC), a resource for investors and traders seeking the latest updates and insights on SomaLogic stock.

SomaLogic, Inc. (Nasdaq: SLGC) is a pioneering company in the field of proteomics, dedicated to transforming healthcare through innovative solutions for detecting and diagnosing diseases. Founded in 2000, SomaLogic leverages decades of aptamer research to offer cutting-edge proteomic technologies that surpass current industry challenges. The company's proprietary platform facilitates the measurement of 11,000 proteins from a single 55-microliter plasma or serum sample, covering a substantial portion of the human proteome.

SomaLogic's mission is to revolutionize life sciences and clinical diagnostics by discovering, developing, and commercializing revolutionary research tools and diagnostic products. Over the past 20 years, the company has worked closely with pharmaceutical firms, academic institutions, and contract research organizations to fuel advancements in drug discovery, disease understanding, and treatment development, particularly in areas such as oncology, diabetes, cardiovascular, liver, and metabolic diseases.

In recent developments, SomaLogic has been at the center of a proposed merger with Standard BioTools, Inc. (Nasdaq: LAB). This transaction has sparked significant debate among stakeholders, with some expressing opposition and filing lawsuits, while others, including SomaLogic's board, advocate for the merger, citing potential value maximization benefits. The final outcome will be determined following stockholder votes and customary closing conditions, with the merger expected to finalize in early 2024.

For more information about SomaLogic, visit somalogic.com or contact their team at information@somalogic.com or 303-625-9000.

News

OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024

Rhea-AI Summary
OncoHost to present new results at AACR Annual Meeting showcasing PROphet® platform's machine learning models for predicting therapeutic benefit and immune-related adverse events in NSCLC patients treated with immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

Rhea-AI Summary
SomaLogic, Inc. (Nasdaq: SLGC) announced stockholder approval for the transaction with Standard BioTools Inc. (Nasdaq: LAB), creating a diversified leader in life sciences tools. The merger is expected to close on January 5, 2024, subject to certain closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Madryn Asset Management Demands SomaLogic’s Board Address Repeated, Unprecedented Adjournments of Tainted Special Meeting

Rhea-AI Summary
Madryn Asset Management, LP (Madryn) demands SomaLogic, Inc. (Nasdaq: SLGC) to answer key questions related to the repeated adjournments of the Special Meeting of Shareholders pertaining to the proposed merger with Standard BioTools Inc. (Nasdaq: LAB). Madryn believes the Board of Directors have betrayed shareholders by delaying the Special Meeting five times for a covert vote-flipping campaign. Madryn has sent a litigation hold to the SomaLogic Board and urges shareholders interested in changing their vote to contact Madryn or the firm’s proxy solicitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Madryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools

Rhea-AI Summary
SomaLogic, Inc. (SOMA) faces challenges as fellow shareholders express concerns over the deal consideration and the company's cash assets, leading to last-minute adjournments of a special meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioTools

Rhea-AI Summary
SomaLogic, Inc. (Nasdaq: SLGC) is urged by leading proxy advisory firms ISS and Glass Lewis to vote 'FOR' the proposed merger with Standard BioTools. The merger is expected to accelerate profitability and value creation, bringing in over $180 million of pro-forma combined revenue, over $500 million of cash, and only $68 million of debt, with $80 million in anticipated cost synergies achieved by 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
acquisition
-
News

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Rhea-AI Summary
Boston Millennia Partners (Nasdaq: BMP) opposes SomaLogic's (Nasdaq: SLGC) merger with Standard BioTools Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
News

Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures

Rhea-AI Summary
Madryn Asset Management, LP (Madryn) urges shareholders to vote 'AGAINST' the proposed merger between SomaLogic, Inc. (SLGC) and Standard BioTools Inc. (LAB). Four significant shareholders, including the company founder, have openly stated their opposition to the merger, highlighting concerns about undervaluation and a flawed process. The recommendation from proxy advisory service ISS only offered 'cautionary support' for the merger, leaving room for shareholders to vote 'AGAINST' the transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders

Rhea-AI Summary
SomaLogic, Inc. (Nasdaq: SLGC) continues to recommend stockholders vote 'FOR' the pending merger with Standard BioTools, emphasizing the benefits of the transaction for all stockholders and the company's future potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.89%
Tags
none
-
News

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools

Rhea-AI Summary
SomaLogic, Inc. (Nasdaq: SLGC) founders Dr. Larry Gold and Dr. Jason Cleveland express opposition to the proposed merger with Standard BioTools, Inc. (Nasdaq: LAB) in a letter to stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
News

SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure

Rhea-AI Summary
SomaLogic, Inc. (Nasdaq: SLGC) responds to Madryn Asset Management's misleading press release regarding the pending merger with Standard BioTools (Nasdaq: LAB).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the market cap of SomaLogic (SLGC)?

The market cap of SomaLogic (SLGC) is approximately 396.2M.

What does SomaLogic, Inc. specialize in?

SomaLogic specializes in proteomics technology, offering advanced solutions for detecting and diagnosing diseases by measuring proteins in the human body.

When was SomaLogic founded?

SomaLogic was founded in 2000.

What recent important event has SomaLogic been involved in?

SomaLogic has been involved in a proposed merger with Standard BioTools, Inc., which has led to significant discussions and legal actions among stakeholders.

What applications does SomaLogic's technology have?

SomaLogic's technology is used in drug discovery, disease research, and treatment development, benefiting areas such as oncology, diabetes, and cardiovascular diseases.

How many proteins can SomaLogic measure with a single sample?

SomaLogic can measure 11,000 proteins from a single 55-microliter plasma or serum sample.

Who can benefit from SomaLogic's proteomics technology?

Pharmaceutical companies, academic institutions, and contract research organizations benefit significantly from SomaLogic's advanced protein detection and analysis capabilities.

What is the mission of SomaLogic?

SomaLogic's mission is to transform healthcare by developing and commercializing revolutionary research tools and diagnostic products in the life sciences.

How can I learn more about SomaLogic?

You can learn more about SomaLogic by visiting their website at somalogic.com or contacting them at information@somalogic.com or 303-625-9000.

What is the status of the merger between SomaLogic and Standard BioTools?

The merger has been approved by SomaLogic stockholders and is expected to close in early 2024, subject to final conditions.

Who are the key executives at SomaLogic?

Key executives include Dr. Larry Gold, the founder, and Dr. Jason Cleveland, the Chief Technology Officer.

Stock SLGC logo
SomaLogic, Inc.

Nasdaq:SLGC

SLGC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SLGC Stock Data

396.23M
175.53M
2.16%
61.71%
3.79%
Health Information Services
Healthcare
Link
United States
Boulder